Reported results
- Cash and cash equivalents as of September 30, 2026, totaled $135.3 million.
- Research and development expense for the three months ended September 30, 2026, was $8.3 million.
- General and administrative expense for the three months ended September 30, 2026, was $6.4 million.
- Net loss attributable to common stockholders was $144.5 million for the three months ended September 30, 2026.
- Revenue for the three months ended September 30, 2026, was $8.0 million.
Guidance
- Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.
- First patients in the FSGS expansion cohort are expected to be dosed in the first quarter of 2027.
- The company expects to present initial data from the briquilimab Phase 1/2 case control study in the fourth quarter of 2026.
Notes
In November 2026, the Company effected a 1-for-30 reverse stock split of its common stock.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
